Obesity Drug Approval Needs A New Paradigm, Stakeholder Group Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Group convened by George Washington University School of Public Health and Health Services recommends a “patient-centered” approach to reviewing obesity drugs that includes assessing the therapies for their risks and benefits for obese individuals who are healthy, have risk factors for co-morbidities or impairments to daily feeling or functioning, or are already sick.